Related Experiment Videos
Exploring new treatment strategies in heart failure
1Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden.
Blood Pressure. Supplement
|November 4, 2000
Summary
Heart failure treatment is improved by blocking the renin-angiotensin system (RAS). Candesartan, an angiotensin II type 1 (AT1) receptor blocker, offers specific blockade and potential benefits for heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure is a leading cause of death and illness, often driven by neuroendocrine activation.
- Current treatments, including beta-blockers and ACE inhibitors, target the sympathetic nervous system and renin-angiotensin system (RAS).
Purpose of the Study:
- To evaluate the clinical benefits of candesartan cilexetil in diverse heart failure patient populations.
- To assess candesartan's efficacy in patients with reduced or preserved left-ventricular systolic function.
Main Methods:
- The CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity) program is an international study.
- It includes 6500 patients across three outcome studies, comparing candesartan cilexetil to placebo.
- Studies focus on patients with ejection fraction ≤40% (ACE inhibitor tolerant/intolerant) and those with preserved systolic function.
Main Results:
- Preliminary data from pilot studies are encouraging.
- The CHARM program aims to define candesartan's role in heart failure management.
- AT1 receptor blockade with candesartan may offer more complete RAS blockade than ACE inhibitors.
Conclusions:
- Candesartan cilexetil shows promise for managing symptomatic heart failure.
- It may provide cardiovascular benefits through specific AT1 receptor blockade and AT2 receptor stimulation.
- The CHARM study is the first to include all heart failure patients eligible for RAS blockade.